Creative Biolabs has extensive experience in all aspects of target development and validation. With our extensive knowledge and advanced platform, we are confident in providing the best target development services for psychiatric disorders to help to meet and exceed your goals.

Despite significant progress in understanding the biological systems and mechanisms involved in psychiatric disorders, the use of knowledge to realize practical gains in psychiatric care has been slow. To fully realize the potential therapeutic impact, it will be critical to increase attention to target development and validation at the early step of the drug discovery process. Creative Biolabs has years' experience in target development and will offer you the best advice and support to advance your drug development programs. With our well-established platform, we provide various high-quality services regarding target development to contribute to your projects' success significantly.

Monoamine Transporter Antagonists

Monoamine transporters, including serotonin, norepinephrine, and dopamine transporters, have been investigated as markers for diagnosis and prognosis of mood, anxiety, and psychotic disorders. In fact, these monoamine transporters could interact with stressful life events and play roles in predisposition to major depression. Based on the well-established link between monoamine transporters and psychiatric disorders, Creative Biolabs offers monoamine transporter inhibitors as the target options for depression and other disorders.

Hypothalamic-Pituitary-adrenal (HPA) Axis Antagonists

Of special interest is the pathophysiology of HPA axis regulation in depression and anxiety disorders. Corticotropin-releasing hormone (CRH) related peptides, gluco- and mineralocorticoids and their receptors play an important role in behavioral, endocrine, and autonomic responses to stress. Selective antagonists have been used experimentally to elucidate the role of HPA, but up to now, the development of specific drugs has been challenging. Creative Biolabs offers the expertise of HPA axis antagonists to meet the specific demands of our customers all over the world.

Glutamate Receptors Regulators

The identification of specific and reliable biomarkers reflecting glutamatergic dysfunction will enable the selection of schizophrenia patients who will benefit more from pharmacotherapies targeting glutamatergic pathways. Glutamate receptors regulators have enriched the understanding of the psychopharmacology of the glutamatergic and peptidergic mechanisms and continued to fuel novel target exploration. Thus, by increasing the knowledge of these diseases and glutamate receptors, Creative Biolabs offers the development of glutamate receptors regulators for our customers' specific targeted-drug development requirements.

Cannabinoid Receptor Antagonist

The endocannabinoid system may play a role in psychiatric disorders and have the potential value of targeting this system in the search for novel and improved medications. Cannabis has profound effects on mood, making it the potential target of psychiatric disorders for the treatment of mood and anxiety disorders. Thus, the cannabinoid receptor antagonist can be developed at Creative Biolabs for the regulation of mood and anxiety states for anxiolytic-drug development.

Others

With long-term expertise in the development of targets, Creative Biolabs is the ideal partner for our global customers. We also offer other target development services for psychotropic drug development propose.

Targets for depression.Fig.1 Targets for depression. (Chávez-Castillo, 2019)

Disorders1 Natur al Pr oduct f or P s y chiatric Drug Disc ov e r y The e xi s ting drugs in p s y chiat r y so f ar ha v e come la r gely f r om se r endipitous disc ov erie s , and the disc ov e r y of these natu r al p r oducts leads to the s ynthesis of the p s y chiatric drugs which sh o w antimanic action and un e xpected f a s t antidep r essant p r ope r tie s . S ta r ting f r om the natu r al p r od - uct s , C r eati v e Biolabs is a v ailable to suppo r t its cu s tomer in terms of technical e xpe r tise f oll o wing b y fu r ther e xtension and modif - cation of earlier drug molecules to inc r ease potency and to dec r ease side e f f ect s .
Disorders2_1 In Silico T echnology f or T a r g e t Pr ediction and Sc r eening Fr om a mo r e global pe r specti v e, C r eati v e Biolabs has the r obu s t in silico technology f or the ta r g e t anal y sis to p r o vide s tructu r e -activi t y in f ormation f or accu r ate side e f f ect p r edictions f or the disc ov e r y of the r esponsible molecular ta r g e t s . In addition, r andom small molecul e -based sc r eening and chemical optimi z ation p r o vide an unp r ecedented oppo r tuni t y to all o w mo r e widesp r ead mining of the drug candidate lib r arie s .
Disorders3 Rational Design of Multitar g e t Drugs Multita r g e t compounds a r e uni f ormly mo r e e f f ecti v e than singl e -ta r g e t compounds f or t r eating multiple p s y chiatric r elated diso r de rs . With the significant g r o w th of multita r g e t drugs in drug disc ov e r y , C r eati v e Biolabs f ocuses on empl o ying the mo s t ad v anced techniques to a t tempt to r ational design and gene r ate multita r g e t drugs which a r e the hope of the n e xt gene r ation of p s y chot r opic s .

Target Development at Creative Biolabs

With our well-established platform, the experienced scientists here at Creative Biolabs are dedicated to helping you with the target development of psychiatric disorders. We also provide other various services regarding psychotropic drug development. To get more information, please feel free to send us an inquiry.

Reference

  1. Chávez-Castillo, M.; et al. Depression as a neuroendocrine disorder: Emerging neuropsychopharmacological approaches beyond monoamines. Advances in Pharmacological and Pharmaceutical Sciences. 2019. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.

Related Sections

Online inquiry

Contact Us